Antibody-drug conjugates containing two or more functional small molecule compounds for enhancing treatment of refractory diseases
By introducing branched structures to link functional small molecules into antibody-drug conjugates, the targeted therapeutic effect of ADCs is enhanced, solving the efficacy and toxicity problems of existing ADCs and enabling wider application in cancer treatment.
Patent Information
- Application Number
- CN202480048034.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-24
- Filing Date
- 2024-05-22
- Publication Date
- 2026-03-24
AI Technical Summary
Improving the efficacy and reducing the toxicity of existing antibody-drug conjugates (ADCs) in cancer treatment and expanding their application in various cancer treatments remains a challenge, especially given the increased toxicity caused by the need to increase the dosing frequency due to the short half-life of chemotherapy drugs.
By linking chemical drugs or functional small molecules through branched structures, antibody-drug conjugates (ADCs) are formed. These ADCs utilize affinity molecules to enhance the affinity of antibodies, thereby achieving synergistic effects with cytotoxic drugs and enhancing the efficacy of targeted therapy.
It improves the antitumor activity of antibody-drug conjugates in vivo, enhances the targeted therapeutic effect on various cancers and refractory diseases, reduces toxicity, and expands the range of therapeutic indications.